bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for fourth-quarter and full-year 2014.
“In 2014, bioMérieux stepped up implementation of its strategic plan, in particular with the acquisition of BioFire in molecular biology, and redeployed its operational organization,” said Chairman Jean-Luc Belingard. “With outcomes in line with the objectives set early in the year, I am especially pleased with the progress made by our Company under the leadership of our new Management Committee, headed by Chief Executive Officer Alexandre Mérieux."
“Today, bioMérieux announced sales growth at constant exchange rates of nearly 9% and of 3.8% at constant scope of consolidation,” said Chief Executive Officer Alexandre Mérieux. “Our sales performance was in line with the target set early in the year, reflecting our competitiveness and ability to adjust to changing market conditions. In addition, with the signature of eight business development agreements in 2014, we reached decisive milestones in the deployment of our roadmap. This robust strategic and operational dynamic, combined with our solid fundamentals, sustained favorable momentum in North America and expanding product portfolio, especially in molecular biology and automated microbiology, enables us to expect sales to accelerate in 2015, and growth of between 4.5% and 6.5% at constant exchange rates and scope of consolidation.”